Back to GENE
Upcoming Economic Outlook - Report Highlights Genetic Technologies Limited (ADR) and Complete Genomics, Inc.

HONG KONG -- (Marketwire) -- 05/29/12 -- Today, www.BrightonMarkets.com announced new reports highlighting Genetic Technologies Limited (ADR) (NASDAQ: GENE) and Complete Genomics, Inc. (NASDAQ: GNOM). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=GENE&cob=GNOM.

With markets in correction mode, investors are looking to quantify an accurate model, weighing positives and negatives of the months ahead. Upcoming negative pressures include China's slowdown, the European recession, the end of the Fed's Operation Twist stimulus program, continued geopolitical risks, election uncertainty, and potential 2013 budget bombshell of tax hikes and spending cuts. Meanwhile, positive offsets are driven by central banks (particularly China) cutting rather than hiking rates, deceleration in fuel and food prices, increase in consumer sentiment and resulting retail sales, signs of improvement in housing sales and new strength in auto production schedules.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Genetic Technologies Limited (ADR) for its current position within the healthcare industry. Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services. The Company's cancer diagnostics business focused on building a sustainable stable of products and services. The Company operates in three divisions: genetic testing, including cancer diagnostics; licensing; and research. The full research report on Genetic Technologies Limited (ADR) (NASDAQ: GENE) is available here: www.BrightonMarkets.com/index.php?coa=GENE.

Brighton Markets has released research on Complete Genomics, Inc. for its changing role within the healthcare industry. Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. The full research report on Complete Genomics, Inc. (NASDAQ: GNOM) is available here: www.BrightonMarkets.com/index.php?cob=GNOM.

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.

Back to GENE
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki